# [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application

> **NCT05458544** · PHASE1,PHASE2 · UNKNOWN · sponsor: **FutureChem** · enrollment: 26 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** [177Lu]Ludotadipep 3.7 GBq

## Key facts

- **NCT ID:** NCT05458544
- **Lead sponsor:** FutureChem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2024-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05458544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05458544, "[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05458544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*